Improving Access to Target Cells
We are proud to present a new service through our partnership with OptiCell Solutions, that improves access to target cells for cell and gene therapies.
OptiCell Solutions specializes in the collection and delivery of high-quality cell samples and the performance of therapeutic apheresis treatments – two areas where there is currently a significant lack of resources in both healthcare and the pharmaceutical industry.
Aiding the Development of ATMPs
Like CliniQnect, OptiCell Solutions possesses extensive knowledge of study coordination, including specific research ethics within CAGT. The focus is to enhance innovative research and the development of new therapies by delivering cells to clinical researchers and the pharmaceutical industry.
Through this partnership, we aim to take a more active role in the development of Advanced Therapy Medicinal Products (ATMPs) by offering high-quality cell samples for research in CAGT – the fastest-growing segment within precision medicine.
Commitment to Patient Care
By reducing waiting times for apheresis treatments and increasing the availability of essential target cells for CAGT development, CliniQnect and OptiCell Solutions contribute to improved patient care and faster treatment timelines. We work together to integrate cutting-edge cell collection with decentralized clinical trials and patient support, enhancing accessibility and the quality of care.
Read more on Apheresis, cell and gene therapy at opticellsolutions.com
